Letters to the Editor:

Standard of Care Should Be Based on Convincing Evidence

Chlorhexidine Recommendations Raise Questions

Malpractice Problem Presents

Medi-Flex Answers Chlorhexidine Questions


Standard of Care Should Be Based on Convincing Evidence

To the Editor:

Two exchanges appeared in the letters section of the Winter 2002-2003 issue, one regarding perioperative beta-blockade and another on ultrasound facilitation of jugular vein cannulation.1-4 They contained a common theme: when should we designate a practice as a Standard of Care?

A Standard of Care demands that all clinicians use the practice without exception. Failure or refusal to observe a Standard of Care due to lack of expertise, lack of money, lack of equipment, or personal preference will no longer be tolerated in quality assurance proceedings or a court of law. Violation becomes indefensible.

Once a practice becomes a Standard of Care, it can never again be tested for efficacy. A Human Subjects Committee would not approve a trial comparing the practice to a control group as controls would necessarily receive substandard care.

It would seem prudent to create a Standard of Care only when the evidence of patient benefit is so convincing that no further examination of the practice need ever be attempted.

Samuel Metz, MD
Philadelphia, PA

References

  1. Kleinman B. Perioperative beta-blockade requires further study—not Standard of Care. APSF Newsletter 2002-03;17:55.
  2. Shojania KG, Wachter RM, McDonald KM. AHRQ responds: promotes beta-blockade, encourages further study. APSF Newsletter 2002-03;17:55-6.
  3. Overdyk FJ. Ultrasound guidance should not be Standard of Care. APSF Newsletter 2002-03;17:56.
  4. LaPorta RF, Berger DB. Ultrasound guidance should not be Standard of Care. APSF Newsletter 2002-03;17:56.

Chlorhexidine Recommendations Raise Questions

To the Editor:

After reading about the use of chlorhexidine (CHG) prep in the Spring 2003 issue the following questions come to mind:

  1. Is CHG potentially useful and possibly preferable for use in preparing the skin area prior to regional nerve blocks?
  2. Is CHG a problem for use on the face and mucous membranes?
  3. Is potential deafness a concern if CHG enters the ear canal?
  4. Should CHG be considered for preparation of the skin prior to insertion of a routine peripheral intravenous catheter or in special circumstances such as an immune compromised patient?

Any information regarding the above questions would be greatly appreciated.

Janet N. Siler, MD
Cinnaminson, NJ


Malpractice Problem Presents

To the Editor:

The Anesthesia Patient Safety Foundation has consistently supported the recommendation that anesthesiologists report any untoward event. In an illustration of the "Law of Unintended Consequences," my group has been placed at risk by this practice. Our malpractice insurer, The Doctor's Insurance Reciprocal, has gone into receivership and ceased paying any expenses or awards. We have obtained another insurance policy (losing 6 months premium), but the policy excludes all ongoing suits and all events which have been reported as presenting potential liability. So any one of us who has reported an event in the past 2 years is liable for any defense cost or award. Such is our reward for following all the rules.

David Hunt, MD
Roanoke, VA


Medi-Flex Answers Chlorhexidine Questions

To the Editor:

Thank you for the opportunity to respond to your readerŐs questions concerning the use of chlorhexidine-based solutions 1) with regional anesthesia, 2) near the eyes and ears, and 3) with routine IV catheter placement.

Neurotoxicity

Chlorhexidine (CHG) or tinctures of CHG antiseptic solutions have been used extensively outside the United States for anesthesia procedures.1 Interestingly, the US Physician Desk Reference (PDR), as of 1984, warns that "chlorhexidine gluconate is for external use only. Keep out of eyes and ears and avoid contact with meninges." Before 1984, the PDR did not have the "avoid contact with meninges" warning. There are two referenced articles for neurotoxicity, both of which are animal studies. One article, published in 1955, was a study with many chemicals and detergent compounds that were injected into the cerebral spinal fluid of monkeys; neurotoxicity was seen with all compounds.2 A second study published in 1984, based on a rat model, involved injecting a CHG solution into the anterior chamber of the eye. This study showed degeneration of adrenergic nerves and suggested that neurotoxic effects on thin myelinated fiber systems in the CNS should be investigated.3 Since the publication of the 1984 PDR warning, an article entitled "Use of a Chlorhexidine Dressing to Reduce Microbial Colonization of Epidural Catheters" from Anesthesiology, 1990, has been released with an epidural catheter study. This CHG-impregnated split dressing absorbs fluid, which allows the release of CHG to the site; in this study there were no cited adverse events.4 The literature states that this dressing is indicated for use with epidural catheters. In 2001, Kinirons and Mimoz published a study comparing a CHG-based antiseptic to povidone-iodine in the reduction of colonization in epidural catheters; interestingly, the patient population was children. Conclusion: CHG was superior to PVP-I.5

Ototoxicity

Deafness has been demonstrated in patients who have undergone vascular myringoplasty operations; the common factor was the use of 0.05% CHG in 70% alcohol for perioperative disinfection of the middle ear. It was thought that the solution had penetrated the membrane, entered the inner ear and caused damage to the cochlea. This direct exposure did result in permanent hearing loss.6 Animal model studies have demonstrated severe vestibular and cochlear damage; the extent of damage was related to the concentration and the duration of exposure.7,8 Other antiseptics with high levels of alcohol or detergent have had similar ototoxicity concerns.9

Ocular Toxicity

Dilute solutions of pure CHG have been used for eye irrigation (0.05%) and as a preservative for eye drops (0.01%). Solutions of higher concentrations and formulations that contain a vehicle for the drug delivery can cause eye damage. Direct application of a topical 2% CHG to the eye demonstrated no changes to the cornea by direct observation or light microscopy; additional studies demonstrated superficial epithelial changes examined by electron microscopy following application of 0.1% and 0.5% CHG solutions.10,11 Concentrations of 2% CHG or greater were clearly toxic to both the corneal epithelium and conjunctiva; a concentration of 1% produced no significant delay in epithelial healing but did cause mild conjunctivitis.12 Accidental splashes entering the eye during normal hand washing procedures using a 4% CHG-detergent based solution have caused irritation but have resolved completely following irrigation of the eye. From the information available, the detergents present in the handwash formulation, or possibly a combination of CHG and excipients are more likely to cause permanent ocular damage than the CHG alone. CHG solutions in an alcohol-base are not appropriate solutions for eye care.

Intravascular Procedures

Intravascular catheter placement is the most common procedure used in caring for hospitalized patients and often leads to catheter-related bloodstream infection (CR-BSI). The use of antiseptic solutions for skin disinfection prior to catheter insertion and site maintenance can help prevent infection, especially in the immunocompromised and intensive care patient (ICU). Catheter-related bloodstream infections double the number of ICU admissions, increase costs an estimated $40,000 per patient survivor, increase the average length of stay by 7 days, and demonstrate mortality rates of 35%.13 Povidone-iodine solution (PVP-I) is the most commonly used skin disinfectant in the US today. But the recent release of a meta-analysis evaluating PVP-I to CHG gluconate indicated that CHG is superior for vascular catheter site care.14

In evaluations of clinical efficacy and cost savings, the implementation of a CHG-based solution will improve patient outcomes and is economically feasible.

Cynthia T Crosby
Director, Clinical Affairs
Medi-Flex, Inc.
Overland Park, KS

References

  1. Adam MN, Dinulescu T, Mathieu P, et al. Comparison of the efficacy of 2 antiseptic solutions in the prevention of infection from peridural catheters. Cah Anesthesiol 1996;44:465-7.
  2. Hurst EW. Adhesive arachnoiditis and vascular blockage caused by detergents and other chemical irritants: an experimental study. In: Stewart MJ, Cameron GR, Oakley CL, Collins DH, MacDonald A, eds. The Journal of Pathology and Bacteriology. London, Oliver and Boyd Ltd., 167-178, 1955.
  3. Henschen A, Olson L. Chlorhexidine-induced dengeneration of adrenergic nerves. Acta Neuropathol 1984;63:18-23.
  4. Shapiro JM, Bond EL, Garman JK. Use of a chlorhexidine dressing to reduce microbial colonization of epidural catheters. Anesthesiology 1990;73:625-31.
  5. Kinirons B, Mimoz O, Lafendi L, et al. Chlorhexidine versus povidone iodine in preventing colonization of continuous epidural catheters in children. Anesthesiology 2001;94:239-44.
  6. Bicknell PG. Sensorineural deafness following myringoplasty operations. J Laryngol Otol 1971;85:957-61.
  7. Morizono T, Johnstone BM, Hadjar E. The ototoxicity of antiseptic (preliminary report). J Otolaryngol Soc Aust 1973;3:550-3.
  8. Igarashi Y, Suzuki JI. Cochlear ototoxicity of chlorhexidine gluconate in cats. Arch Otorhinolaryngol 1985;242:167-76.
  9. Morizono T, Johnstone BM, Entjep H. Sensorineural deafness caused by perioperative antiseptics. Otologia Fukuoka 1974;20:97-9.
  10. Browne RK, Anderson AN, Charvez BW, Azzarello RJ. Ophthalmic response to chlorhexidine digluconated in rabbits. Toxicol Appl Pharmacol 1975;32:621-7.
  11. Dormans JA, van Logten MJ. The effect of ophthalmic preservatives on the corneal epithelium of the rabbit: A scanning electron microscopical study. Toxicol Appl Pharmacol 1982;62:251-61.
  12. Hamill MB, Osato MS, Wilhelmus KR. Experimental evaluation of chlorhexidine gluconate for ocular antisepsis. Antimicrob Agents Chemother 1984;26:793-6.
  13. Ross VM, Orr PA. Prevention of infections related to central venous catheters. Crit Care Nurs Q 1997;20:79-88.
  14. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med 2002;136:792-801.